Serum IL-33 Concentrations and the IL-12/IFN-? Axis According to Therapeutic Strategy in Rheumatoid Arthritis
Medical Principles and Practice · 2026-11-09
DOI: 10.1159/mpp/adpag041 ↗Abstract
Abstract Introduction: Interleukin-33 (IL-33) is involved in inflammatory pathways relevant to rheumatoid arthritis (RA) and may interact with the IL-12/interferon-gamma (IFN-γ) axis. However, the relationship between circulating IL-33 concentrations and different therapeutic strategies remains incompletely understood. Subjects and Methods: In this prospective observational study with cross-sectional analysis, 189 consecutive RA patients were stratified according to treatment: methotrexate (MTX), MTX plus TNF inhibitors (MTX+TNFi), tocilizumab (TCZ), and DMARD-naïve patients. Serum IL-33 concentrations were measured by ELISA. Disease activity indices (DAS28-ESR, CDAI, SDAI), inflammatory markers, and serum IL-12 and IFN-γ levels were assessed. Results: IL-33 concentrations differed across therapeutic groups, with the highest levels observed in DMARD-naïve patients and lower levels in those receiving biologic therapy, particularly TCZ. IL-33 was associated with disease activity parameters and showed a modest positive correlation with IL-12. IFN-γ concentrations also differed among treatment groups, with the lowest levels observed in TCZ-treated patients. Conclusions: Serum IL-33 concentrations varied across therapeutic groups in rheumatoid arthritis and were associated with selected indicators of inflammatory activity. Further studies are needed to clarify the role of IL-33 in the immunopathology of rheumatoid arthritis.
EUVIMED